While advances in artificial intelligence have made protein design widely accessible, protein production and characterization remain a bottleneck. Protease-cleavable affinity tags are commonly used t...

While advances in artificial intelligence have made protein design widely accessible, protein production and characterization remain a bottleneck. Protease-cleavable affinity tags are commonly used t....

YouTube video by AI Proteins

April 14, 2026 | How is BindCraft, the automated pipeline for de novo protein binder design, changing the protein design industry? Martin Pacesa, assistant professor of pharmacology at the University ...

Mar 06, 2026

Both experts in the field, one with an academic view and one from industry, they discuss what can be done today with protein design, new innovations coming in the next year or two, and how they think ...

Nature’s salary survey finds that industry researchers are more positive about their careers. Academia must raise its game.

introduction and membership Boston Protein Design and Modeling Club (BPDMC) is a community of computational protein engineers and modelers from both academia and industry. While we are based in Boston...

YouTube video by Provolut

AI Proteins raises $42M Series A for minibinder drug development, led by Mission BioCapital & Santé Ventures. CEO Chris Bahl aims to target TNFR1 with first candidate.

What if medicines could "speak" directly to your cells? Protein designer and TED Fellow Chris Bahl introduces a new generation of miniproteins: AI-designed medicines that can deliver detailed instruct...

introduction and membership Boston Protein Design and Modeling Club (BPDMC) is a community of computational protein engineers and modelers from both academia and industry. While we are based in Boston...

YouTube video by Instituto de Estudos Avançados da USP

Computational design of molecular recognition remains challenging despite advances in deep learning. The design of proteins that bind to small molecules has been particularly difficult because it requ...

AI Proteins, Inc., a pioneering company utilizing artificial intelligence to design novel protein therapeutics, announces the appointment of its found

Bristol Myers Squibb has

Bristol Myers Squibb partners with AI Proteins for miniprotein development, with up to $400M in milestones. Terns Pharmaceuticals reports positive Phase 1 data for TERN-701. Six biotechs seek Hong Kon...

Bristol Myers Squibb has

AI Proteins, Inc., a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, today announced that

AI Proteins, Inc., a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, today announced that

introduction and membership Boston Protein Design and Modeling Club (BPDMC) is a community of computational protein engineers and modelers from both academia and industry. While we are based in Boston...

Share your videos with friends, family, and the world